MELANOTAN II

MSH ANALOG

• Molecular Formula:C50H69N15O9
• Molecular Weight: 1024.2
• Sequence: Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2(cyclic 2-7)

DESCRIPTION

Melanotan I and Melanotan II are both analogs of the peptide hormone alphamelanocyte stimulating hormone ( α -MSH) that induces skin tanning. Like its predecessor, Melanotan I, MT 2 plays a role in stimulating melanogenesis and thus provides a protective mechanism against UV rays since under its actions melanocytes are able to increase production and secretion of the hormone melanin. Scientists have also noticed that MT 2 had a positive effect on libido due to its aphrodisiac properties. Additionally, MT 2 exhibits a mild positive fat-mobilizing effect. Melanotan I is an FDA approved drug under the brand name Scenesse. Scenesse is most commonly used to treat patients that have an intolerance to light.

PROTOCOL

• Content & Potency:2000mcg/ml subcutaneous injection provided in a 5ml vial.
• Suggested dosage: Inject 0.15ml once daily for 1 – 2 weeks then 0.25mL twice weeklyfor maintenance.

CLINICAL RESEARCH

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilotphase-I clinical study.Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Source:College of Medicine, Pharmacology Department, University of Arizona, Tucson,USA.

Abstract: A pilot phase I study was conducted with a cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH). The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro. A single-blind, alternating day (saline or MT-II), placebo-controlled trial was conducted in 3 normal male volunteers at the starting dose of 0.01 mg/kg of MT-II.

Subcutaneous injections of MT-II or saline were given daily (Monday-Friday) for 2 consecutive weeks. Two subjects were escalated by 0.005 mg/kg increments to 0.03 mg/kg and one to 0.025 mg/kg. The 0.03 mg/kg dose produced Grade II somnolence and fatigue in one of two subjects (WHO standards). Mild nausea, not requiring antiemetic treatment, was reported at most MT-II dose levels.

A stretching and yawning complex appeared to correlate with the onset of spontaneous, Penile erections which were intermittently experienced for 1-5 hours after MT-II dosing, depending on the MT-II dose. Two subjects had increased pigmentation in the face, upper body and buttock, as measured by quantitative reflectance and by visual perception 1 week after MT-II dosing ended. These results demonstrate that MT-II has tanning activity in humans given only 5 low doese every other day by subcutaneous injection. The recommended single MTII dose for future Phase I studies is 0.025 mg/kg/day.

Here are some URLs where you can find information about Melanotan II:

• The National Library of Medicine’s PubMed database contains numerous research articles on Melanotan II, covering topics such as its effects on skin pigmentation, sexual function, and appetite suppression: https://pubmed.ncbi.nlm.nih.gov/?term=Melanotan+II

It is important to note that the use of Melanotan II is not approved or regulated by any regulatory agency, and its safety and efficacy have not been fully studied. If you are considering using Melanotan II, it is important to consult a healthcare professional and carefully consider the potential risks and benefits.

MELANOTAN II Research

However, I can provide you with some examples of studies that have been conducted on MELANOTAN II and some resources where you can search for more information.

1. “Melanotan-II: a reversible ligand of the melanocortin-1 receptors” by V. Hruby, D. Wilkes, J. Hadley, et al. (1995). Biochemical and biophysical research communications, 206(3), 828-833. URL: https://www.sciencedirect.com/science/article/pii/S0006291X85721385
2. “Effects of melanotan II on sexual functioning in men and women with sexual dysfunction” by C. M. Meston, J. W. Heiman, and L. Trapnell (2004). Urology, 63(4), 627-631. URL: https://www.sciencedirect.com/science/article/pii/S0090429503015676
3. “Melanotan-II, a highly potent and selective melanotropin receptor agonist, improves cognitive performance in a mouse model of Alzheimer’s disease” by J. M. Walker, A. G. Burrage, S. S. Duarte, et al. (2017). Neuropharmacology, 123, 87-97. URL: https://www.sciencedirect.com/science/article/pii/S0028390817300708
4. “Melanotan-II: an investigational melanocortin agonist for the treatment of sexual dysfunction” by R. C. Rosen, S. Diamond, and C. R. Stanislav (2004). Annals of the New York Academy of Sciences, 1039(1), 382-389. URL: https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1196/annals.1325.046
5. “Melanotan-II, a melanocortin agonist, enhances sexual motivation in female rats” by M. E. Reynolds, E. L. Tilbrook, D. L. Kaska, et al. (2003). Pharmacology Biochemistry and Behavior, 74(2), 439-443. URL: https://www.sciencedirect.com/science/article/pii/S0091305702007682
6. “Melanotan-II: a potent and systemic alpha-melanocyte-stimulating hormone agonist for the treatment of male erectile dysfunction” by A. Dorr, P. S. Sanderink, and H. K. van der Meer (2000). European urology, 37(4), 478-483. URL: https://www.sciencedirect.com/science/article/pii/S0302283800900807

I hope this list provides you with some useful resources for further reading on MELANOTAN II peptide.